Cardlytics Inc (NASDAQ:CDLX) Director Bryce Youngren Sells 174,695 Shares

Share on StockTwits

Cardlytics Inc (NASDAQ:CDLX) Director Bryce Youngren sold 174,695 shares of the stock in a transaction that occurred on Wednesday, August 14th. The shares were sold at an average price of $33.70, for a total value of $5,887,221.50. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.

Bryce Youngren also recently made the following trade(s):

  • On Thursday, August 8th, Bryce Youngren sold 100,000 shares of Cardlytics stock. The shares were sold at an average price of $31.54, for a total value of $3,154,000.00.
  • On Thursday, July 25th, Bryce Youngren sold 88,030 shares of Cardlytics stock. The shares were sold at an average price of $29.12, for a total value of $2,563,433.60.
  • On Friday, July 19th, Bryce Youngren sold 34,274 shares of Cardlytics stock. The shares were sold at an average price of $27.92, for a total value of $956,930.08.
  • On Wednesday, July 17th, Bryce Youngren sold 68,727 shares of Cardlytics stock. The shares were sold at an average price of $27.66, for a total value of $1,900,988.82.
  • On Thursday, June 6th, Bryce Youngren sold 75,284 shares of Cardlytics stock. The shares were sold at an average price of $24.10, for a total value of $1,814,344.40.
  • On Tuesday, May 28th, Bryce Youngren sold 100,000 shares of Cardlytics stock. The shares were sold at an average price of $23.04, for a total value of $2,304,000.00.

Shares of CDLX traded down $0.67 during mid-day trading on Thursday, reaching $33.26. The company’s stock had a trading volume of 129,964 shares, compared to its average volume of 251,716. Cardlytics Inc has a 1-year low of $9.80 and a 1-year high of $34.30. The stock has a market cap of $711.84 million, a PE ratio of -15.54 and a beta of 1.76. The business’s 50-day moving average price is $28.68. The company has a current ratio of 2.37, a quick ratio of 2.37 and a debt-to-equity ratio of 0.99.

Cardlytics (NASDAQ:CDLX) last released its quarterly earnings data on Thursday, August 8th. The company reported ($0.12) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.35) by $0.23. Cardlytics had a negative return on equity of 64.83% and a negative net margin of 19.60%. The company had revenue of $48.73 million during the quarter, compared to analysts’ expectations of $43.77 million. During the same period last year, the firm posted ($0.21) earnings per share. The business’s revenue was up 37.0% on a year-over-year basis. As a group, research analysts predict that Cardlytics Inc will post -1.08 EPS for the current fiscal year.

Several research analysts recently commented on CDLX shares. Bank of America reissued a “buy” rating and set a $32.00 price target (up from $22.00) on shares of Cardlytics in a research report on Wednesday, July 24th. JPMorgan Chase & Co. set a $43.00 price objective on Cardlytics and gave the company a “buy” rating in a research report on Friday, August 9th. ValuEngine cut Cardlytics from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, April 23rd. Raymond James raised their price objective on Cardlytics from $24.00 to $40.00 and gave the company an “outperform” rating in a research report on Friday, August 9th. Finally, SunTrust Banks raised their price objective on Cardlytics from $25.00 to $35.00 and gave the company a “buy” rating in a research report on Friday, August 9th. One analyst has rated the stock with a hold rating and eight have issued a buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $33.29.

Several institutional investors and hedge funds have recently added to or reduced their stakes in CDLX. BlackRock Inc. lifted its position in shares of Cardlytics by 94.2% in the second quarter. BlackRock Inc. now owns 903,619 shares of the company’s stock valued at $23,476,000 after buying an additional 438,215 shares during the last quarter. Grantham Mayo Van Otterloo & Co. LLC acquired a new stake in Cardlytics during the 2nd quarter worth approximately $10,392,000. Vanguard Group Inc. lifted its holdings in Cardlytics by 46.1% during the 2nd quarter. Vanguard Group Inc. now owns 755,132 shares of the company’s stock worth $19,618,000 after purchasing an additional 238,211 shares during the last quarter. Frontier Capital Management Co. LLC lifted its holdings in Cardlytics by 11.5% during the 1st quarter. Frontier Capital Management Co. LLC now owns 1,631,248 shares of the company’s stock worth $26,981,000 after purchasing an additional 168,471 shares during the last quarter. Finally, Tygh Capital Management Inc. acquired a new stake in Cardlytics during the 1st quarter worth approximately $2,488,000. 70.43% of the stock is owned by institutional investors.

About Cardlytics

Cardlytics, Inc operates a purchase intelligence platform in the United States and the United Kingdom. It operates in two segments, Cardlytics Direct and Other Platform Solutions. The company's platform is the Cardlytics Direct solution, a proprietary native bank advertising channel that enables marketers to reach consumers through their trusted and frequently visited online and mobile banking channels.

Recommended Story: Trading Stocks – What are percentage gainers?

Insider Buying and Selling by Quarter for Cardlytics (NASDAQ:CDLX)

Receive News & Ratings for Cardlytics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardlytics and related companies with MarketBeat.com's FREE daily email newsletter.